Related references
Note: Only part of the references are listed.A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia
Stephen H. Petersdorf et al.
BLOOD (2013)
Current strategies in immunotherapy for acute myeloid leukemia
Felix S. Lichtenegger et al.
IMMUNOTHERAPY (2013)
T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct
M. Aigner et al.
LEUKEMIA (2013)
Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel
Ursula Creutzig et al.
BLOOD (2012)
Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab
Matthias Klinger et al.
BLOOD (2012)
Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML
Jessica A. Pollard et al.
BLOOD (2012)
Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL
Max S. Topp et al.
BLOOD (2012)
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
Roland B. Walter et al.
BLOOD (2012)
Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens
Matthias Friedrich et al.
MOLECULAR CANCER THERAPEUTICS (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
Generation, selection and preclinical characterization of an Fc-optimized FLT3 antibody for the treatment of myeloid leukemia
M. Hofmann et al.
LEUKEMIA (2012)
Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease
Jean-Claude Chomel et al.
BLOOD (2011)
High CD33 expression levels in acute myeloid leukemia cells carrying the nucleophosmin (NPM1) mutation
Maria Stefania De Propris et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Targeted Therapy With the T-Cell-Engaging Antibody Blinatumomab of Chemotherapy-Refractory Minimal Residual Disease in B-Lineage Acute Lymphoblastic Leukemia Patients Results in High Response Rate and Prolonged Leukemia-Free Survival
Max S. Topp et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia
R. Handgretinger et al.
LEUKEMIA (2011)
An evidence for adhesion-mediated acquisition of acute myeloid leukemic stem cell-like immaturities
Keiji Funayama et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials
David Grimwade et al.
BLOOD (2010)
Acute Myeloid Leukemia With Biallelic CEBPA Gene Mutations and Normal Karyotype Represents a Distinct Genetic Entity Associated With a Favorable Clinical Outcome
Annika Dufour et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells
Ralf Lutterbuese et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
In vitro biology of human myeloid leukemia
Hector Mayani et al.
LEUKEMIA RESEARCH (2009)
Rapid and sensitive screening for CEBPA mutations in acute myeloid leukaemia
Tobias Benthaus et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
Ralf Bargou et al.
SCIENCE (2008)
Establishing long-term cultures with self-renewing acute myeloid leukemia stem/progenitor cells
Djoke van Gosliga et al.
EXPERIMENTAL HEMATOLOGY (2007)
Hematopoietic stem cells express multiple myeloid markers: implications for the origin and targeted therapy of acute myeloid leukemia
DC Taussig et al.
BLOOD (2005)
Flow cytometric amalysis of different CD14 epitopes can help identify immature monocytic populations
DT Yang et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2005)
Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia
EJ Feldman et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity
RB Walter et al.
BLOOD (2005)
CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance
ML Linenberger
LEUKEMIA (2005)
Ex vivo expansion of human hematopoietic stem cells by direct delivery of the HOXB4 homeoprotein
S Amsellem et al.
NATURE MEDICINE (2003)
Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines
J Geginat et al.
BLOOD (2003)
Share Paper
